Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens

Cytokinetics, Incorporated

05/11/2025 21:14

Overview

Cytokinetics Q3 net loss widens to $306.2 mln, driven by debt conversion expense

Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year

Cytokinetics prepares for potential U.S. launch of aficamten pending FDA approval

Outlook

Company expects EMA decision on aficamten MAA in 1H 2026

Company updates 2025 GAAP operating expense guidance to $680 mln-$700 mln

Cytokinetics prepares for aficamten U.S. commercial launch post-PDUFA date

Result Drivers

FDA INTERACTIONS - Co progressing towards Dec 2025 PDUFA date for aficamten, with strategic commercial preparations underway

R&D EXPENSES: $99.2 million for the third quarter of 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$306.18 mln
Q3 Basic EPS
-$2.55
Q3 Operating Expenses
$168.69 mln
Q3 Operating Income
-$166.76 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cytokinetics Inc is $79.00, about 24.5% above its November 4 closing price of $59.62

Press Release: ID:nGNX8Mgh2m

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)